title: Erythrocyte zinc in hyperthyroidism: reflection of integrated thyroid hormone levels over the previous few months.
abstract: Red blood cell (RBC) zinc (Zn) concentration was measured by atomic absorption spectrophotometry in 28 healthy volunteers, in 46 patients with hyperthyroidism, and in 6 patients with hypothyroidism. The mean (+/- SD) RBC Zn concentration in euthyroid controls was 11.4 +/- 1.5 mg/L RBC, and the normal range defined as the mean +/- 2 SD was 8.5 to 14.3 mg/L RBC. The mean RBC Zn in patients with hyperthyroidism was decreased to 6.4 +/- 1.6 mg/L RBC, and 43 (93%) had low values. The mean RBC Zn in patients with hypothyroidism was not different from that in the controls. There was a significant negative correlation between the concentrations of RBC Zn and those of both plasma thyroxine (T4; r = -0.73) and plasma 3,5,3'-triiodothyronine (T3; r = -0.70). After the treatment of 17 hyperthyroid patients with antithyroid drugs, both mean plasma T4 and T3 levels became normal within 4 weeks, but the normalization of RBC Zn lagged about 2 months behind them. The RBC Zn levels significantly correlated with both the plasma T4 and T3 levels obtained 0, 4, 8, and 12 weeks prior to the RBC sampling, and the highest correlation was observed between the RBC Zn levels and plasma T4 and T3 levels measured 8 weeks previously. These data suggest that RBC Zn concentration in hyperthyroid patients reflects a patient's mean thyroid hormone level over the preceding several months as glycosylated hemoglobin level does in diabetic patients.
authors.affiliation: Department of Clinical Biology and Hormonal Regulation, Tohoku University School of Medicine, Sendai, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yoshida
authors.forename: Y
authors.initials: Y
authors.lastname: Kiso
authors.forename: T K
authors.initials: TK
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Kaise
authors.forename: N
authors.initials: N
authors.lastname: Kaise
authors.forename: Y
authors.initials: Y
authors.lastname: Itagaki
authors.forename: M
authors.initials: M
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Sakurada
authors.forename: K
authors.initials: K
authors.lastname: Yoshinaga
mesh_terms: D000328:Adult; D004912:Erythrocytes / Q000378:metabolism*; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy / Q000378:metabolism*; D007037:Hypothyroidism / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D011441:Propylthiouracil / Q000627:therapeutic use; D013739:Testosterone / Q000032:analysis; D013963:Thyroid Hormones / Q000097:blood* / Q000502:physiology; D013972:Thyrotropin / Q000032:analysis; D013997:Time Factors; D015032:Zinc / Q000032:analysis / Q000097:blood*
chemical_list: D013963:Thyroid Hormones; D013739:Testosterone; D008713:Methimazole; D011441:Propylthiouracil; D013972:Thyrotropin; D015032:Zinc